Earnings summaries and quarterly performance for MDxHealth.
Executive leadership at MDxHealth.
Board of directors at MDxHealth.
Research analysts who have asked questions during MDxHealth earnings calls.
Jason Bednar
Piper Sandler Companies
4 questions for MDXH
Also covers: ALGN, COO, EDAP +15 more
Andrew Brackmann
William Blair & Company, L.L.C.
3 questions for MDXH
Also covers: ADPT, AWH, BDSX +11 more
Thomas Vranken
KBC Securities
3 questions for MDXH
Mark Massaro
BTIG, LLC
2 questions for MDXH
Also covers: ADPT, AKYA, BNGO +18 more
Thomas Flaten
Lake Street Capital Markets
2 questions for MDXH
Also covers: ACHV, AQST, ASRT +13 more
Dan Brennan
UBS
1 question for MDXH
Also covers: A, DHR, MYGN +7 more
Daniel Brennan
TD Cowen
1 question for MDXH
Also covers: A, ADPT, AVTR +24 more
Nelson Cox
Lake Street Capital Markets
1 question for MDXH
Also covers: AORT, AQST, CVRX +6 more
Vidyun Bais
BTIG
1 question for MDXH
Also covers: AKYA, BNGO, CERS +5 more
Recent press releases and 8-K filings for MDXH.
MDxHealth Reports Strong Q3 2025 Results and Reaffirms Full-Year Guidance
MDXH
Earnings
Guidance Update
M&A
- MDxHealth SA reported Q3 2025 revenues of $27.4 million, an 18% increase over the prior year period, contributing to nine-month revenues of $78.3 million, up 20% year-to-date.
- The company achieved positive adjusted EBITDA of $1.0 million for Q3 2025, marking a $4.8 million improvement from the prior year.
- Net loss for Q3 2025 improved by 28% to $8.0 million.
- MDxHealth SA reaffirmed its full-year revenue guidance of $108 million to $110 million, anticipating Q4 and full-year growth to meet or exceed 20%.
- The company completed the acquisition of the Exosome Diagnostics business from Bio-Techne Corporation on September 15, 2025.
Nov 12, 2025, 9:17 PM
MDxHealth Announces Closing of ExoDx Diagnostics Acquisition
MDXH
M&A
New Projects/Investments
- MDxHealth SA announced the closing of its acquisition of the ExoDx business from Bio-Techne Corporation on September 15, 2025.
- The acquisition, which includes the ExoDx Prostate test and related assets, has a total consideration of $15 million.
- The payment structure involves $5 million in stock paid at closing and $2.5 million annually over the next four years, with 50% in cash and 50% in cash or stock at MDxHealth’s discretion.
Sep 16, 2025, 12:03 AM
Quarterly earnings call transcripts for MDxHealth.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more
Let Fintool AI Agent track MDxHealth's earnings for you
Get instant analysis when filings drop